Quick Answer
Fulcrum Therapeutics, Inc. reported Stockholders Equity of $349.00 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $349.00M | +43.6% |
| 2024 | $243.03M | +3.3% |
| 2023 | $235.19M | +18.2% |
| 2022 | $198.94M | -6.0% |
| 2021 | $211.54M | +122.2% |
| 2020 | $95.18M | +9.2% |
| 2019 | $87.15M | +236.9% |
| 2018 | -$63.67M | -91.4% |
| 2017 | -$33.27M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $198.37M | -22.9% | -7.5% |
| June 30, 2025 | $214.38M | -21.7% | -6.2% |
| March 31, 2025 | $228.49M | +7.0% | -6.0% |
| December 31, 2024 | $243.03M | +3.3% | -5.5% |
| September 30, 2024 | $257.29M | +0.7% | -6.0% |
| June 30, 2024 | $273.79M | -0.6% | +28.2% |
| March 31, 2024 | $213.59M | -27.9% | -9.2% |
| December 31, 2023 | $235.19M | +18.2% | -7.9% |
- Fulcrum Therapeutics, Inc. showed an increase of +43.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Fulcrum Therapeutics, Inc.’s stockholders equity has grown by 1149.2% (from -$33.27 million to $349.00 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: